Abstracts Archive - Page 852 of 2425 - ACR Meeting Abstracts

Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Min Jung Kim¹, Anna Shin ², Seonghwan Shin ², You-Jung Ha ³, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ¹ and Eun Ha Kang ³, ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…
Abstract Number: 1405 • 2019 ACR/ARP Annual Meeting
Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab
Lovisa Lyngfelt¹, Malin Erlandsson ², Karin Andersson ², Sofia Silfverswärd ² and Maria Bokarewa ², ¹Department of Rheumatology and Inflammation Research at Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Adipose tissue is an important player in cardiovascular (CV) morbidity. Thermogenic brown adipocytes, rich with uncoupling protein 1 (UCP1), increase metabolic and CV health.…
Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Maxime Verhoeven¹, Janneke Tekstra ¹, Attila Pethö-Schramm ², Michelle Borm ³, Jacob van Laar ¹, Floris Lafeber ¹, Johannes Bijlsma ¹, Johannes Jacobs ¹ and Paco Welsing ¹, ¹UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ²Hoffmann-La Roche, Basel, Basel, Switzerland, ³Roche Nederland BV, Woerden, Netherlands
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
Peter Taylor¹, Janet Pope ², Kei Ikeda ³, Xiang Zhang ⁴, Bochao Jia ⁴, Hong Zhang ⁵, Amanda Quebe ⁴, Yun-Fei Chen ⁴, Carol Gaich ⁴, Thorsten Holzkaemper ⁴, Anabela Cardoso ⁴ and Anthony Sebba ⁶, ¹University of Oxford, Oxford, United Kingdom, ²Western University, London, ON, Canada, ³Chiba University Hospital, Chiba, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵TechData Services, King of Prussia, PA, ⁶University of South Florida, Palm Harbor, FL
Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
Abstract Number: 1408 • 2019 ACR/ARP Annual Meeting
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Alexandre Sepriano ², Josef Smolen ¹, Désirée van der Heijde ², Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Medical University of Vienna, Vienna, Austria, ²Leiden University Medical Center, Leiden, Netherlands, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Via a systematic literature review of contemporary efficacy data of pharmacological therapies in RA we sought to inform the 2019 update of the EULAR…
Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1 Comparative evidence…
Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Alberto Migliore¹, Giuseppe Pompilio ², Davide Integlia ², Joe Zhuo ³ and Evo Alemao ⁴, ¹Unit of Rheumatology Ospedale S. Pietro Fatebenefratelli, Rome, Italy, ²Isheo Srl, Rome, Italy, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Princeton
Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…
Abstract Number: 1411 • 2019 ACR/ARP Annual Meeting
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy
Yushiro Endo¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Ayako Nishino ¹, Momoko Okamoto ¹, Shimpei Morimoto ², Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Yukitaka Ueki ⁴, Tamami Yoshitama ⁵, Nobutaka Eiraku ⁶, Naoki Matsuoka ⁷, Akitomo Okada ⁸, Keita Fujikawa ⁹, Hiroaki Hamada ¹⁰, Tomomi Tsuru ¹¹, Shuji Nagano ¹², Yojiro Arinobu ¹³, Toshihiko Hidaka ¹⁴, Yoshifumi Tada ¹⁵ and Atsushi Kawakami ¹⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University Hospital Clinical Research Centre, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ⁵Yoshitama Clinic for Rheumatic Diseases, Kirishima, Japan, ⁶Eiraku Clinic for Rheumatic Diseases, Kagoshima, Japan, ⁷Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ¹⁰Miyazaki University Hospital, Miyazaki, Japan, ¹¹PS clinic, Fukuoka, Japan, ¹²Aso Iizuka Hospital, Iizuka, Japan, ¹³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ¹⁴Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹⁵Saga University Hospital, Saga, Japan, ¹⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Rheumatoid arthritis (RA) occasionally overlaps Sjogren’s syndrome (SS), and RA patients with secondary SS have a higher disease activity of RA and worse joint…
Abstract Number: 1412 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study
Stanley Cohen¹, Janet Pope ², Boulos Haraoui ³, Eduardo Mysler ⁴, Annette Diehl ⁵, Tatjana Lukic ⁶, Shixue Liu ⁷, Lori Stockert ⁵, Sujatha Menon ⁸ and Edward Keystone ⁹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Western University, London, ON, Canada, ³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁴Organización Médica de Investigación, Buenos Aires, Argentina, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Shanghai, China (People's Republic), ⁸Pfizer Inc, Groton, CT, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The tofacitinib modified-release (MR) 11 mg once daily (QD) formulation was first…
Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Naonobu Sugiyama ³, Noriko Iikuni ⁴, Koshika Soma ⁵, Harry Shi ⁶, Eduardo Mysler ⁷, Robert J. Moots ⁸, Josef Smolen ⁹ and Roy Fleischmann ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
Abstract Number: 1414 • 2019 ACR/ARP Annual Meeting
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
Frank Behrens¹, Werner A Biewer ², Gerd Burmester ³, Martin Feuchtenberger ⁴, Michael W. Hofmann ⁵, Peter Kästner ⁶, Herbert Kellner ⁷, Ramona König ⁸, Anke Liebhaber ⁹, Christina Luig ¹⁰, Regina Max ¹¹, Patrizia Sternad ¹², Hans-Peter Tony ¹³ and Christopher Amberger ¹⁴, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Rheumatologische Schwerpunktpraxis Saarbrücken, Saarbrücken, Germany, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Chugai Pharma Europe Ltd., Frankfurt/Main, Germany, ⁶MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁷Praxis Prof. Herbert Kellner, Munich, Germany, ⁸Justus-Liebig-Universität Giessen and Kerckhoff-Klinik-Forschungs-GmbH, Giessen, Germany, ⁹Internistisch-Rheumatologische Arztpraxis, Halle, Halle, Germany, ¹⁰Roche Pharma AG, Rheumatologie, Grenzach-Wyhlen, Germany, ¹¹Universitätsklinikum Heidelberg, Heidelberg, Germany, ¹²Gemeinschaftspraxis, Planegg, Planegg, Germany, ¹³Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ¹⁴Rheumatologische Gemeinschaftspraxis Dr. Pick/Dr. Amberger, Bad Neuenahr, Germany
Background/Purpose: In rheumatoid arthritis (RA), the proinflammatory cytokine IL-6 is associated with mental disorders such as depression and anxiety.1 Furthermore, depression and anxiety are comorbidities…
Abstract Number: 1415 • 2019 ACR/ARP Annual Meeting
Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
Aurelia Luissi¹, Florencia Pierini ², Ignacio Gandino ², Eliana Botta ³, Fernando Brites ³, Laura Boero ³, Maximiliano Martin ³, Tomas Meroño ³, Soledad saez ⁴, Walter Tetzlaff ³, Fernando Sommerfleck ⁵, Gustavo Citera ⁶, Javier Rosa ⁷, Patricia Sorroche ⁴ and Enrique Soriano ⁸, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Capital Federal, Argentina, ³Universidad de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Sanatorio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁸Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular diseases. Recent studies found that RA patients present dysfunctional high density lipoproteins (HDL)…
Abstract Number: 1416 • 2019 ACR/ARP Annual Meeting
B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo ², Carlota García-Hoz ³, Israel Nieto-Gañán ⁴, Victoria Navarro-Compán ⁵, Ana Martínez-Feito ⁶, javier Bachiller ¹, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ¹, Paloma Lapuente-Suanzes ⁸, Dora Pascual-Salcedo ², Alejandro Balsa ⁷, Garbiñe Roy ⁴, Mónica Vázquez Díaz ¹, Luisa María Villar ⁴, Chamaida Plasencia ⁷ and Eulalia Rodríguez-Martín ⁴, ¹Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ³Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁴Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁵University Hospital La Paz, IdiPaz, Madrid, Spain, ⁶Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ⁸University Hospital Ramón y Cajal, Madrid
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory and heterogeneous autoimmune disorder of unknown etiology characterized by progressive joint damage. Although TNF inhibitors (TNFi) have…
Abstract Number: 1417 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Philip Baer ², Denis Choquette ³, Wojciech Olszynski ⁴, Rafat Faraawi ⁵, Louis Bessette ⁶, Milton Baker ⁷, Raman Rai ⁵, John Kelsall ⁸, Larissa Lisnevskaia ⁹, Jodie Reis ⁴, Keltie Anderson ⁴, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²Independent Rheumatology Practice, Scarborough, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal, University of Montreal, Québec, Canada., Montreal, QC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Laval University, Laval, QC, Canada, ⁷Vancouver Island Health Authority, Victoria, BC, Canada, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Lakeridge Health Centre, Oshawa, ON, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose was…
Abstract Number: 1418 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Rafat Faraawi ², Louis Bessette ³, Andrew Chow ⁴, Jodie Reis ⁵, Keltie Anderson ⁵, Emmanouil Rampakakis ⁶, Meagan Rachich ⁷, Odalis Asin-Milan ⁷, Allen Lehman ⁷ and Francois Nantel⁷, ¹Memorial University, Newfoundland, NL, Canada, ²McMaster University, Hamilton, ON, Canada, ³Laval University, Laval, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶JSS Medical Research, Montreal, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled rheumatoid arthritis (RA) patients treated with either subcutaneous golimumab (GLM-SC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].